Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Traws Pharma (TRAW) EPS (Basic) (2016 - 2025)

Traws Pharma (TRAW) has disclosed EPS (Basic) for 14 consecutive years, with -$0.34 as the latest value for Q3 2025.

  • On a quarterly basis, EPS (Basic) rose 77.18% to -$0.34 in Q3 2025 year-over-year; TTM through Sep 2025 was $5.41, a 109.77% increase, with the full-year FY2024 number at -$35.21, down 56.0% from a year prior.
  • EPS (Basic) was -$0.34 for Q3 2025 at Traws Pharma, down from -$0.15 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $3.73 in Q4 2024 to a low of -$31.53 in Q2 2024.
  • A 5-year average of -$3.05 and a median of -$0.26 in 2022 define the central range for EPS (Basic).
  • Peak YoY movement for EPS (Basic): plummeted 15665.0% in 2024, then skyrocketed 136.66% in 2025.
  • Traws Pharma's EPS (Basic) stood at -$0.16 in 2021, then plummeted by 62.5% to -$0.26 in 2022, then plummeted by 6226.92% to -$16.45 in 2023, then surged by 122.67% to $3.73 in 2024, then plummeted by 109.12% to -$0.34 in 2025.
  • Per Business Quant, the three most recent readings for TRAW's EPS (Basic) are -$0.34 (Q3 2025), -$0.15 (Q2 2025), and $2.17 (Q1 2025).